Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes

International Immunology

Volumn 16, Issue 9, 2004, Pages 1283-1294

  Chin, Cynthia S ^a,b   Miller, Catriona H T ^a   Graham, Laura ^a   Parviz, Maryam ^a,c   Zacur, Sharline ^a   Patel, Bina ^a   Duong, Angie ^a   Bear, Harry D ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b ST VINCENT S HOSPITAL   (United States)

^c Cancer Care Northwest   (United States)

Author keywords

4T07; Adoptive immunotherapy; Bryostatin; Ionomycin; L selectin

Indexed keywords

BRYOSTATIN 1; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; INTERLEUKIN 2; IONOMYCIN; L SELECTIN; PADGEM PROTEIN; TUMOR ANTIGEN; TUMOR VACCINE;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL SEPARATION; CELL STIMULATION; CELL TRANSFER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; GENE ACTIVATION; HYPOTHESIS; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE CELL; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; TISSUE PREPARATION; TUMOR CELL; TUMOR REGRESSION;

ANIMALS; CYTOKINES; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY, ADOPTIVE; IONOMYCIN; L-SELECTIN; LACTONES; LYMPHOCYTE ACTIVATION; MACROLIDES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; T-LYMPHOCYTES;

EID: 4544258659     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/dxh130     Document Type: Article

References (39)

1. Tuttle, T. M., Inge, T. H., Bethke, K. P. and Bear, H. D. 1992. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1. Cancer Res. 52:548.
2. Chin, C. S., Graham, L. J., Hamad, G. G., George, K. R. and Bear, H. D. 2001. Bryostatin/ionomycin-activated T cells mediate regression of established tumors. J. Surg. Res. 98:108.
3. Cantrell, D. 1996. T cell antigen receptor signal transduction pathways. Ann. Rev. Immunol. 14:259.
4. Petit, G. R., Herald, C. L., Doubek, D. L., Herald, D. L., Arnold, E. and Clardy, J. 1982. Isolation and structure of byrostatin 1. J. Am. Chem. Soc. 104:6846.
5. 3H]bryostatin 1 and analogs to calcium-dependent and calcium-independent protien kinase C isozymes. Mol. Pharmacol. 46:374.
6. Lorenzo, P. S., Bogi, K., Hugh, K. M., Beheshti, M., Bhattacharyya, D., Garfield, S. H., Pettit, G. R. and Blumberg, P. M. 1999. Differential roles of the tandem C1 domains of protein kinase Cδ in the biphasic down-regulation induced by bryostatin 1. Cancer Res. 59:6137.
7. Lin, H., Chen, C., Li, X. and Chen, B. D. 2002. Activation of the MEK/MAPK pathway is involved in bryostatin 1-induced monocytic differentiation and up-regulation of X-linked inhibitor of apoptosis protein. Exp. Cell Res. 272:192.
8. Chatila, T., Silverman, L., Miller, R. and Geha, R, 1989. Mechanisms of T cell activation by calcium ionophore, ionomycin. J. Immunol. 143:1283.
9. Kjaergaard, J. and Shu, S. 1999. Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but requires down-regulation of L-selectin expression. J. Immunol. 163:751.
10. - helper cells that secretes interleukin 2 (IL-2), IL-3, IL-4, and interferon γ. J. Exp. Med. 174:547.
11. low cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. J. Immunol. 160:3444.
12. Hu, H. M., Urba, W. J. and Fox, B. A. 1998. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J. Immunol. 161:3133.
13. Parviz, M., Chin, C. S., Graham, L. J., Miller, C., Lee, C., George, K. and Bear, H. D. 2003. Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model. Cancer Immunol. Immunotherapy 52:12.
14. Chin, C. S. and Bear, H. D. 2002. Sentinel node mapping identifies vaccine-draining lymph nodes with tumor-specific immunologic activity. Ann. Surg. Onc. 9:94.
15. Fleming, M. D., Bear, H. D., Lipshy, K., Kostuchenko, P. J., Portocarero, D., McFadden, A. W. and Barrett, S. K. 1995. Adoptive transfer of bryostatin-activated tumor-sensitized lymphocytes prevents or destroys tumor metastases without expansion in vitro. J. Immunother Emphasis Tumor Immunol. 3:147.
16. Roger, P. R., Dubey, C. and Swain, S. L. 2000. Qualitative changes accompany memory T cell generation: faster, more effective responses at lower doses of antigen. J. Immunol. 164:2338.
17. Luquman, M. and Bottomly, K. 1992. Activation requirements for CD4+ T cells differing in CD45R expression. J. Immunol. 149:2300.
18. Horgan, K. J., van Seventer, G. A., Shimizu, Y. and Shaw, S. 1990. Hyporesponsiveness of "naive" (CD45RA+) human T cells to multiple receptor-mediated stimuli but augmentation of responses by co-stimuli. Eur. J. Immunol. 20:1111.
19. Mullbacher, A. and Flynn, K. 1996: Aspects of cytotoxic T cell memory. Immunol. Rev. 150:113.
20. Bruno, L., Kirberg, J. and von Boehmer, H. 1995. On the cellular basis of immunological T cell memory. Immunity 2:37.
21. Byrne, J. A., Butler, J. L. and Cooper, M. D. 1988. Differential activation requirements for virgin and memory T cells. J. Immunol. 141:3249.
22. Philgren, M. P., Dubois, M., Tomkowiak, T., Sjogren, T. and Marvel, J. 1997. Resting memory CD8+ T cells are hyperreactive to antigenic challenge in vitro. J. Exp. Med. 184:2141.
23. Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D. and Levitsky, H. 1998. The central role of CD4+ T cells in the antitumor immune response. J. Exp. Med. 188:2357.
24. Dobrzanski, M. J., Reome, J. B. and Dutton, R. W. 1999. Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases. J. Immunol. 162:6671.
25. Winter, H., Hu, H. M., McClain, K., Urba, W. J. and Fox, B. A. 2001. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-γ in vaccine-induced antitumor immunity versus adoptive immunotherapy. J. Immunol. 166:7370.
26. Tsung, K., Meko, J. B., Peplinski, G. R., Tsung, Y. L. and Norton, J. A. 1997. IL-12 induces T helper 1-directed antitumor response. J. Immunol. 158:3359.
27. Aruga, A. E., Aruga, K., Tanigawa, D. K., Bishop, G. A., Sondak, V. K. and Chang, A. E. 1997. Type 1 vs type 2 cytokine release by Vβ T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J. Immunol. 158:3359.
28. Lowes, M. A., Bishop, G. A., Crotty, K., Barnetson, R. S. and Halliday, G. M. 1997. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. J. Invest. Dermatol. 108:914.
29. Zitovogel, L., Mayordomo, J. I., Tjandrawan, T., DeLeo, A. B., Clarke, M. R., Lotze, M. T. and Storkus, W. J. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation and T helper cell 1-associated cytokines. J. Exp. Med. 183:87.
30. Kawakami, Y., Eliyahu, S., Delgado, C. H. et al. 1994. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl Acad. Sci. USA 91:6458.
31. North, R. J. 1982. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor cells. J. Exp. Med. 155:1063.
32. Proietti, E., Greco, G., Garrone, B. et al. 1998. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J. Clin. Invest. 101:429.
33. high suppressor T cells vediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy. J. Immunol. 169:4811.
34. Tuttle, T. M., Inge, T. H., Bethke, K. P., McCrady, C. W., Pettit, G. R. and Bear, H. D. 1992. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1. Cancer Res. 52:548.
35. Wang, Q. J., Bhattacharyya, D., Garfield, S., Narco, K., Marquez, V. E. and Blumberg, P. M. 1999. Differential localization of protein kinase C delta by phobol esters and related compounds using a fusion protein with green fluorescent protein. J. Biol. Chem. 274:37233.
36. Lorenzo, P. S., Beheshti, M., Pettit, G. R., Stone, J. C. and Blumberg, P. M. 2000. The guanine nucleotide exchange factor RASGRP is a high-affinity target for diacylglycerol and phorbol esters. Mol. Pharm. 57:840.
37. Ebinu, J. O., Stang, S. L., Teixeira, C. et al. 2000. RasGRP links T-cell receptor signaling to Ras. Blood 95:3199.
38. Wang, S., Wang, Z., Boise, L. H., Dent, P. and Grant, S. 1999, Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL. Leukemia 13:1564.
39. Lin, H., Chen, C., Li, X. and Chen, B. D. 2002. Activation of the MEK/MAPK pathway is involved in bryostatin-1 induced monocytic differentiation and up-regulation of X-linked inhibitor of apoptosis protein. Exper. Cell Res. 272:192.